Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted ...

The application is supported by the phase 3 SAFFRON trial, in which savolitinib plus osimertinib improved progression-free ...

Investigators stated that the results support the proposed mechanism that both retained HER2 expression and elevated CD47 levels may drive efficacy through enhanced antibody-dependent cellular ...

In an interview live from the 2026 International Myeloma Society (IMS) Annual Meeting, Sagar Lonial, MD, discussed the FDA approval of iberdomide, for which data were presented at the meeting, and the ...